Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. (Q43780769)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 February 2014

Language	Label	Description	Also known as
English	Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.	scientific article published on 27 February 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

phase II clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

Alexander Dobrovic

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Michael Michael

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Shane C White

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Ehtesham Abdi

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Louise Nott

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Phillip Clingan

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Allan Zimet

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Peter Button

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Daniel Gregory

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Benjamin Solomon

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Hongdo Do

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

27 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Asia Pacific Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

4-14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

The role of amphiregulin in breast cancer.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Epidermal growth factor receptors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Chemotherapy for advanced non-small cell lung cancer patients with performance status 2.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a phase I/II trial

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets.

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1111%2FAJCO.12178

21 January 2018

Identifiers

10.1111/AJCO.12178

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24575793%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43780769&oldid=2103270885"